Literature DB >> 26884939

miRNA-101 inhibits ovarian cancer cells proliferation and invasion by down-regulating expression of SOCS-2.

Hong-Bin Zheng1, Xiao-Gang Zheng1, Bao-Ping Liu1.   

Abstract

OBJECTIVE: To investigate the expression of miRNA-101 in normal and malignant ovarian tissues and cells as well as its impact on the proliferation and invasion of human ovarian cancer H08910 and SKOV3 cell lines.
METHODS: Real time polymerase chain reaction (RT-PCR) was employed to detect the miR-101 and SOCS-2 expression in 20 separate ovarian cancer tissues and para-carcinoma tissues, human ovarian cancer cells (H08910 and SKOV3) and normal human ovarian epithelial cells (HUM-CELL-0088). After H08910 and SKOV3 ovarian cancer cells were respectively transfected with miR-NC (H08910/NC and SKOV3/NC) and miR-101 (H08910/miR-101 and SKOV3/miR-101), Western Blot was employed to detect the SOCS-2 expression in transfected cells. CCK-8 and clone formation and Transwell assays were employed to determine the proliferation and invasion ability of wild type and transfected ovarian cancer cells.
RESULTS: The expression of miR-101 in ovarian cancer tissues and cells was significantly lower than that in para-carcinoma tissues (t=19.12, P=0.002) and normal human ovarian epithelial cells (HUM-CELL-0088) (F=14.37, P=0.000), respectively. In contrast, the SOCS-2 expression in ovarian cancer tissues and cells was significantly higher than that in para-carcinoma tissues (t=25.03, P=0.000) and HUM-CELL-0088 cells (F=14.9, P=0.000) by Western Blotting analysis, respectively. Compared with wild type and empty vector transfected cells, the expression of SOCS-2 was significantly decreased in miR-101 transfected H08910 (t=10.9, P=0.001) and SKOV3 cells (t=21.03, P=0.000). The results of CCK-8, clone formation and Transwell assays revealed that the proliferation and invasion ability of ovarian cancer cells was markedly inhibited by the transfection of miR-101.
CONCLUSION: MiR-101 was validated to be reduced and SOCS-2 expression increased in ovarian cancer tissues and cells. The over expression of miR-101 can remarkably reduce the in vitro proliferation and invasion ability of ovarian cancer cells through the down-regulation of SOCS-2.

Entities:  

Keywords:  SOCS-2; cell proliferation; miRNA-101; ovarian cancer

Year:  2015        PMID: 26884939      PMCID: PMC4723784     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  18 in total

1.  Effects of luteolin on the inhibition of proliferation and induction of apoptosis in human myeloid leukaemia cells.

Authors:  W G Ko; T H Kang; S J Lee; Y C Kim; B H Lee
Journal:  Phytother Res       Date:  2002-05       Impact factor: 5.878

2.  Low expression of SOCS-1 and SOCS-3 is a poor prognostic indicator for gastric cancer patients.

Authors:  Guanghua Li; Jianbo Xu; Zhao Wang; Yujie Yuan; Yin Li; Shirong Cai; Yulong He
Journal:  J Cancer Res Clin Oncol       Date:  2014-09-28       Impact factor: 4.553

3.  β-Catenin expression is regulated by an IRES-dependent mechanism and stimulated by paclitaxel in human ovarian cancer cells.

Authors:  Qianyun Fu; Zhen Chen; Xiaohai Gong; Yanfei Cai; Yun Chen; Xin Ma; Ruiyu Zhu; Jian Jin
Journal:  Biochem Biophys Res Commun       Date:  2015-04-04       Impact factor: 3.575

4.  MiR-101 inhibits cell growth and tumorigenesis of Helicobacter pylori related gastric cancer by repression of SOCS2.

Authors:  Xiaoying Zhou; Yang Xia; Lin Li; Guoxin Zhang
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

5.  Modification of the amino terminus of a class II epitope confers resistance to degradation by CD13 on dendritic cells and enhances presentation to T cells.

Authors:  X Dong; B An; L Salvucci Kierstead; W J Storkus; A A Amoscato; R D Salter
Journal:  J Immunol       Date:  2000-01-01       Impact factor: 5.422

6.  PreImplantation factor promotes neuroprotection by targeting microRNA let-7.

Authors:  Martin Mueller; Jichun Zhou; Lihua Yang; Yuan Gao; Fuju Wu; Andreina Schoeberlein; Daniel Surbek; Eytan R Barnea; Michael Paidas; Yingqun Huang
Journal:  Proc Natl Acad Sci U S A       Date:  2014-09-09       Impact factor: 11.205

7.  Tyrosinase inhibitory polyphenols from roots of Morus lhou.

Authors:  Seong Hun Jeong; Young Bae Ryu; Marcus J Curtis-Long; Hyung Won Ryu; Yoon Su Baek; Jae Eun Kang; Woo Song Lee; Ki Hun Park
Journal:  J Agric Food Chem       Date:  2009-02-25       Impact factor: 5.279

8.  Suppressor of cytokine signaling (SOCS) genes are silenced by DNA hypermethylation and histone deacetylation and regulate response to radiotherapy in cervical cancer cells.

Authors:  Moon-Hong Kim; Moon-Sun Kim; Wonwoo Kim; Mi Ae Kang; Nicholas A Cacalano; Soon-Beom Kang; Young-Joo Shin; Jae-Hoon Jeong
Journal:  PLoS One       Date:  2015-04-07       Impact factor: 3.240

9.  Potentiating antilymphoma efficacy of chemotherapy using a liposome for integration of CD20 targeting, ultra-violet irradiation polymerizing, and controlled drug delivery.

Authors:  Cong Wu; Huafei Li; He Zhao; Weiwei Zhang; Yan Chen; Zhanyi Yue; Qiong Lu; Yuxiang Wan; Xiaoyu Tian; Anmei Deng
Journal:  Nanoscale Res Lett       Date:  2014-08-28       Impact factor: 4.703

10.  The Effect of Tumor Microenvironment on Autophagy and Sensitivity to Targeted Therapy in EGFR-Mutated Lung Adenocarcinoma.

Authors:  Yuan-Yuan Li; Sze-Kwan Lam; Chun-Yan Zheng; James Chung-Man Ho
Journal:  J Cancer       Date:  2015-02-25       Impact factor: 4.207

View more
  19 in total

1.  MicroRNA-152 inhibits ovarian cancer cell proliferation and migration and may infer improved outcomes in ovarian cancer through targeting FOXP1.

Authors:  Wen Qin; Wei Xie; Qinglin He; Tianwei Sun; Chaoguo Meng; Kunling Yang; Yuanfu Luo; Dongmei Yang
Journal:  Exp Ther Med       Date:  2017-11-17       Impact factor: 2.447

Review 2.  MicroRNAs in gynecological cancers: Small molecules with big implications.

Authors:  Sanjeev K Srivastava; Aamir Ahmad; Haseeb Zubair; Orlandric Miree; Seema Singh; Rodney P Rocconi; Jennifer Scalici; Ajay P Singh
Journal:  Cancer Lett       Date:  2017-05-24       Impact factor: 8.679

3.  Cancer exosome-derived miR-9 and miR-181a promote the development of early-stage MDSCs via interfering with SOCS3 and PIAS3 respectively in breast cancer.

Authors:  Mengmeng Jiang; Wenwen Zhang; Rui Zhang; Pengpeng Liu; Yingnan Ye; Wenwen Yu; Xiaojing Guo; Jinpu Yu
Journal:  Oncogene       Date:  2020-05-12       Impact factor: 9.867

4.  Knockdown of Myeloid Cell Leukemia-1 by MicroRNA-101 Increases Sensitivity of A549 Lung Cancer Cells to Etoposide.

Authors:  Mahshid Shahverdi; Jamal Amri; Hadi Karami; Maryam Baazm
Journal:  Iran J Med Sci       Date:  2021-07

5.  Apigenin sensitizes BEL-7402/ADM cells to doxorubicin through inhibiting miR-101/Nrf2 pathway.

Authors:  Ai-Mei Gao; Xiao-Yu Zhang; Zun-Ping Ke
Journal:  Oncotarget       Date:  2017-05-30

6.  LncRNA PTAR promotes EMT and invasion-metastasis in serous ovarian cancer by competitively binding miR-101-3p to regulate ZEB1 expression.

Authors:  Haihai Liang; Tong Yu; Yue Han; Hua Jiang; Chengyu Wang; Tianyi You; Xiaoguang Zhao; Huitong Shan; Rui Yang; Lida Yang; Hongli Shan; Yunyan Gu
Journal:  Mol Cancer       Date:  2018-08-11       Impact factor: 27.401

7.  MicroRNA-126 exerts antitumor functions in ovarian cancer by targeting EGFL7 and affecting epithelial-to-mesenchymal transition and ERK/MAPK signaling pathway.

Authors:  Yuhua Zhang; Xiaobo Qin; Juan Jiang; Wenjie Zhao
Journal:  Oncol Lett       Date:  2020-05-29       Impact factor: 2.967

8.  MiR-101 inhibits ovarian carcinogenesis by repressing the expression of brain-derived neurotrophic factor.

Authors:  Ying Xu; Lei Xu; Jianbin Zheng; Lei Geng; Shuping Zhao
Journal:  FEBS Open Bio       Date:  2017-08-29       Impact factor: 2.693

9.  MicroRNA-101 regulates T-cell acute lymphoblastic leukemia progression and chemotherapeutic sensitivity by targeting Notch1.

Authors:  Lu Qian; Wanggang Zhang; Bo Lei; Aili He; Lianhong Ye; Xingzhou Li; Xin Dong
Journal:  Oncol Rep       Date:  2016-09-21       Impact factor: 3.906

10.  MicroRNA‑665 suppresses the growth and migration of ovarian cancer cells by targeting HOXA10.

Authors:  Jinhui Liu; Yi Jiang; Yicong Wan; Shulin Zhou; Sunita Thapa; Wenjun Cheng
Journal:  Mol Med Rep       Date:  2018-07-05       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.